4 completed. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Midnight Pharma, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users 200 mg almorexant, 400 mg almorexant, 1000 mg almorexant - Abuse Potential Study | Phase 1 | Completed | Midnight Pharma, LLC | 42 | 2009-09-01 | 2016-02-12 |
| Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia almorexant, Placebo, zolpidem - Primary Insomnia | Phase 3 | Completed | Midnight Pharma, LLC | 709 | 2008-03-01 | 2016-03-14 |
| Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia ACT-078573 oral capsules at 25 and 100 mg and matching placebo, ACT-078573 and matching placebo - Chronic Primary Insomnia | Phase 2 | Completed | Midnight Pharma, LLC | 112 | 2007-12-01 | 2016-03-14 |
| Almorexant in Primary Insomnia almorexant - Insomnia, Primary Insomnia | Phase 1 | Completed | Midnight Pharma, LLC | 161 | 2006-05-01 | 2016-02-12 |
Sleep Initiation and Maintenance Disorders (3)
almorexant (4) · Zolpidem (2)
Austria (2) · Denmark (2) · Finland (2) · Germany (2) · Israel (2) · Spain (2) · Sweden (2) · Switzerland (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · France (1) · Hungary (1)
Edward M Sellers, MD, PhD (1) · Eleornora Chiossi, MSc (1) · Fabrice Kramer, MD (1) · Georg Dorffner, Prof. Dr. (1) · James K. Walsh, PhD (1) · Jasper Dingemanse, PhD (1) · Petra Hoever, MSc (1) · Raymond Cluydts, Dr. (1)